A golden anniversary: highlights of the 50th annual meeting of the American Society of Clinical Oncology

McVie, Gordon; Nailor, Audrey
June 2014
Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1
Academic Journal
The 50th Annual Meeting of the American Society of Clinical Oncology showed a shift in the culture of cancer research, moving towards multidisciplinary, integrated, and patient-centric work. Hormone-sensitive cancers were particularly highlighted at this meeting, and impressive strides were made in the previously underserved areas of the lung and thyroid cancer. Interestingly, immunotherapy was one of the strongest themes to emerge.


Related Articles

  • Immunotherapy Moving from Hype Cycle into Remissions. Breindl, Anette // BioWorld Today;6/6/2012, Vol. 23 Issue 109, p1 

    The article focuses on a session on immunotherapy held at the 2012 American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois. Dendreon's immunotherapy product Provenge has been approved in 2010, while many companies failed in their late-stage trials with immunotherapies including...

  • Feature Analysis: ASCO meeting 2009: is maintenance the new paradigm for the treatment of NSCLC?  // PharmaWatch: Monthly Review;Jul2009, Vol. 8 Issue 7, p8 

    Information about the 45th annual meeting of the American Society of Clinical Oncology (ASCO), held in Orlando, Florida is presented. Several papers presented at the conference focuses on the maintenance therapy for non-small cell lung cancer (NSCLC). Also presented in the meeting were studies...

  • Focus: Lung cancer resources. Johnson, Cynthia // Medicine on the Net;Nov2008, Vol. 14 Issue 11, p17 

    The article reviews several web sites that provide information on lung cancer including Cancer.Net from American Society of Clinical Oncology (ASCO), and Lungcancer.com, and Lungcancer.org from CancerCare.

  • NewLink's Phase II NSCLC Data Another Immunotherapy Boost. Boggs, Jennifer // BioWorld Today;6/3/2013, Vol. 24 Issue 105, p1 

    The article reports on the presentation of data from the phase II trial of NewLink Genetics Corporation's tergenpumatucel-L, a candidate from the firm's HyperAcute immunotherapy platform, for the treatment of metastatic or recurrent non-small-cell lung cancer (NSCLC) at the American Society of...

  • ASCO 2005: Emphasis on cancer prevention, quality care. Guthrie, Ellen Whipple // Pharmacy Today;Jul2005, Vol. 11 Issue 7, p5 

    This article presents information about the 41st annual meeting of the American Society of Clinical Oncology held in Orlando, Florida, on May 13-17, 2005. More than 28,000 attendees discussed the latest in cancer research, prevention, care, and treatment. This year, 31 educational and scientific...

  • Targeting Cancer Cells.  // Newsweek (Atlantic Edition);06/05/2000 (Atlantic Edition), Vol. 135 Issue 23, p89 

    Mentions a drug that targets cancer cells, IMC-C225. Success of preliminary trials reported at an American Society of Clinical Oncology conference in spring 2000; How the drug works to shrink tumor growth.

  • ASCO: Aromatase inhibitors alone or after tamoxifen recommended for postmenopausal HR-positive breast cancer.  // Hem/Onc Today;8/25/2010, Vol. 11 Issue 16, p16 

    This article reports on the updated guideline issued by the American Society of Clinical Oncology on the use of adjuvant hormone therapy for postmenopausal women with hormone receptor-positive breast cancer.

  • Targeted Therapies Take Aim Against Lung Cancer and Melanoma. Mitka, Mike // JAMA: Journal of the American Medical Association;8/11/2010, Vol. 304 Issue 6, p624 

    The article discusses the highlights of the June 2010 annual meeting of the American Society of Clinical Oncology (ASCO), giving particular focus on research studies on targeted therapies for the treatment of lung cancer and melanoma. Findings from a phase 3 study, which recruited patients with...

  • ASCO meeting highlights works in progress. McCann, Jean // JNCI: Journal of the National Cancer Institute;6/15/94, Vol. 86 Issue 12, p892 

    Reports on the highlights of the 1994 meeting of the American Society of Clinical Oncology. Introduction of a new paradigm for early stage breast cancer; Emphasis on works in progress on major phase trials; Discussion on the widespread use of bone marrow transplantation for the treatment of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics